Journal of Clinical Oncology
Articles in this Issue
A real-world clinicogenomic study of androgen receptor mutations and co-mutations in prostate cancer: Clinical implications.
73 Background: While most prostate cancer (PCa) patients (pts) initially respond to androgen deprivation therapy, resistance commonly develops, resulting...
The nature of progression on long term active surveillance for confirmed Gleason grade group 1 prostate cancer in the modern era.
360 Background: Gleason Grade Group 1 (GG1), or Gleason 3+3, prostate cancer (PCa), are considered low-risk, and unlikely to lead to major adverse outcome...
A phase 2/3 multicenter trial evaluating safety and efficacy of a new mucoadhesive gemcitabine suspension for ablation of upper tract urothelial carcinoma.
TPS889 Background: Patients with large, multifocal, or frequently recurrent low-grade (LG) upper tract urothelial carcinoma (UTUC) often require nephroure...
A multi-centre review of the use of adjuvant pembrolizumab for renal cell carcinoma.
484 Background: In patients with increased risk of recurrence after surgical resection of renal cell carcinoma (RCC), adjuvant treatment with pembrolizuma...
TP53 Y220C mutations in advanced urothelial bladder cancer (UBC): A genomic landscape study.
821 Background: TP53 is the most frequently altered gene in human cancers. Novel agents targeting the pathogenic TP53-...
Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100.
869 Background: In the JAVELIN Bladder 100 phase 3 trial, avelumab 1LM + best supportive care (BSC) significantly prolonged overall survival (OS) and prog...
Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression on prior androgen receptor pathway inhibitor.
TPS299 Background: Intraductal adenocarcinoma of the prostate (IDC-P) serves as an aggressive pathological pattern of prostate cancer. Previous retrospect...
Muscle invasive bladder cancer treatment selection in an emerging treatment era: A patient preference study.
753 Background: Patients with muscle invasive bladder cancer (MIBC) face a preference-sensitive choice among various treatment alternatives. MIBC is typic...
Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC).
562 Background: ICI-based therapies are the cornerstone of treatment for advanced RCC. While many studies have focused on tumor-based biomarkers, circulat...
The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) + ipilimumab (ipi).
545 Background: Over the last decade, immune checkpoint therapy (ICT) has become the cornerstone of first-line treatment for mccRCC. Despite the widesprea...
Real-world persistence and adherence to relugolix (REL) in US patients with nonmetastatic (nm) vs metastatic (m) prostate cancer (PC).
88 Background: REL is the only oral androgen deprivation therapy (ADT) for patients (pts) with PC, offering an alternative to long-acting injectable/impla...
Efficacy of neoadjuvant/induction (NAC) chemotherapy in nonmetastatic muscle-invasive bladder cancer treated with chemoradiotherapy (CRT): A systematic review and meta-analysis.
814 Background: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the established standard for nonmetastatic muscle-invasive bladder c...
Real-world analysis of pembrolizumab utilization and characteristics of patients being prescribed treatment in early stage RCC.
480 Background: In the United States, adjuvant pembrolizumab was approved on November 17, 2021, for patients with RCC with intermediate-high (T2N0M0-G4, T...
Application of radiomics as a risk stratification tool in node positive penile cancer.
3 Background: The risk level of lymph node metastasis in penile cancer is determined using the Graafland criteria which determines how patients are treate...
Genomic alterations and their pathologic responses in high-risk localized prostate cancer (HRLPC) in subprotocol 1 of the Genomic Umbrella Neoadjuvant study (GUNS).
403 Background: GUNS (NCT04812366) is a multicenter adaptive phase II trial evaluating 24 weeks of biomarker-selected, neoadjuvant androgen receptor pathw...
Assessing practice gaps and challenges for immunotherapy integration in treatment of metastatic urothelial carcinoma.
694 Background: The approval of pembrolizumab with enfortumab vedotin in the first-line setting has shifted the treatment paradigm for patients with metas...
Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial.
268 Background: A decline in prostate-specific antigen (PSA) following androgen deprivation therapy (ADT) is a well-established prognostic marker in metas...
Adrenal androgens and overall survival (OS) in men with castration-resistant prostate cancer (CRPC) treated with enzalutamide without (ENZ) or with abiraterone and prednisone (ENZ/AAP) (Alliance).
230 Background: DHEA, testosterone (T) and androstenedione (AD) are adrenal androgens that can drive CRPC. HSD3B1 encodes for 3β-h...
EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma.
9 Background: Patients with locally advanced or metastatic penile squamous cell carcinoma (la/mPC) have a poor prognosis w...
Safety and efficacy of intravesical bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer.
787 Background: Patients treated with bladder-preserving therapy for muscle-invasive bladder cancer are at risk of developing recurrent non-muscle-invasiv...
Association of myeloid-derived suppressor cell (MDSC) dynamics with clinical response to nivolumab in metastatic clear cell renal carcinoma patients (mRCC): Results from the I-RENE Meet-URO 8 study.
586 Background: Immune checkpoint blockade is a standard-of-care treatment for mRCC patients, but the immune mechanisms driving clinical benefit remain un...
Frequent overexpression of NECTIN-4 in CNS metastases from urothelial carcinoma.
804 Background: The combination of enfortumab vedotin plus pembrolizumab (EV/P) has become the new standard of care for advanced or metastatic urothelial...
Clinical characteristics and treatment patterns of patients with muscle invasive bladder cancer: A real-world cohort study.
698 Background: Due to the evolving treatment landscape for muscle-invasive bladder cancer (MIBC), a better understanding of current treatment patterns am...
Neoadjuvant androgen deprivation therapy with enzalutamide plus the glucocorticoid receptor modulator relacorilant versus placebo for patients with high-risk localized prostate cancer.
TPS436 Background: Despite definitive local treatment, high risk localized prostate cancer (PC) patients (pts) have a 36-46% risk of biochemical recurrenc...
Risk stratification using the Decipher 22-gene genomic classifier (GC) and digital pathology artificial intelligence (DPAI) in nearly 10,000 localized prostate cancer patients.
408 Background: DPAI models have recently demonstrated the potential to improve risk stratification beyond routine clinical and pathologic variables. Howe...